SCHEMBL6849643

SCHEMBL6849643

CN(CCCCCc1ccccc1)C(=O)C1CCc2[nH]cnc2C1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 3/20 0.44
ALDH1A1 P00352 2/20 0.44
MEN1 O00255 1/20 0.44
TSHR P16473 1/20 0.44
KMT2A Q03164 1/20 0.44
GRIN2B Q13224 3/20 0.41
GRIN1 Q05586 2/20 0.41
SIGMAR1 Q99720 3/20 0.38
ABL1 P00519 1/20 0.37
RIN1 Q13671 1/20 0.37
HTR3A P46098 2/20 0.37
ADRA2A P08913 1/20 0.37
ADRA2B P18089 1/20 0.37
ADRA2C P18825 1/20 0.37
SLC6A4 P31645 1/20 0.37
OPRK1 P41145 1/20 0.37
HTR2B P41595 1/20 0.37
KCNH2 Q12809 1/20 0.37
HTR3E A5X5Y0 1/20 0.37
HTR3B O95264 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6851076 0.89 MAPK9 (0.36) KDM4EALDH1A1MEN1TSHRKMT2A
SCHEMBL6850920 0.89 NPC1 (0.41) KDM4EALDH1A1MEN1TSHRKMT2A
SCHEMBL6851053 0.85 POLB (0.46) KDM4EMEN1TSHRKMT2AABL1
SCHEMBL6846872 0.81 ADRA1A (0.40) MEN1KMT2AHTR3AADRA2AADRA2B
SCHEMBL6849720 0.81 HTR1B (0.45) KDM4EALDH1A1MEN1TSHRKMT2A
SCHEMBL6850932 0.78 PPARD (0.41) KDM4EALDH1A1MEN1TSHRKMT2A
SCHEMBL6846933 0.78 S1PR1 (0.37) ALDH1A1KMT2AOPRK1
SCHEMBL6852825 0.77 ADRA1A (0.41) KDM4EALDH1A1TSHRHTR3AADRA2A
SCHEMBL6851354 0.76 SLC6A4 (0.41) KDM4EHTR3AADRA2AADRA2BADRA2C
SCHEMBL7008256 0.75 ADRA1A (0.43) KDM4EALDH1A1HTR3AADRA2AADRA2B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6756384-B2 TREATMENT OF DISEASES AND DISORDERS RELATED TO THE HISTAMINE H3 RECEPTOR. NOVO NORDISK A/S (DK) 2004-06-29 US disclosed
US-20030135056-A1 Imidazole compounds HIGH POINT PHARMACEUTICALS, LLC 2003-07-17 US disclosed
EP-1268484-A1 CONDENSED IMIDAZOLES AS HISTAMINE H3 RECEPTOR LIGANDS NOVO NORDISK A/S (DK) 2003-01-02 EP disclosed
US-6437147-B1 FOR THERAPY OF DISEASES OF CENTRAL NERVOUS SYSTEM, PERIPHERAL NERVOUS SYSTEM, CARDIOVASCULAR SYSTEM, PULMONARY SYSTEM, GASTROINTESTINAL SYSTEM AND ENDOCRINOLOGICAL SYSTEM NOVO NORDISK (DK) 2002-08-20 US disclosed
US-20020058659-A1 Imidazole compounds HIGH POINT PHARMACEUTICALS, LLC 2002-05-16 US disclosed
WO-2001068652-A1 CONDENSED IMIDAZOLES AS HISTAMINE H3 RECEPTOR LIGANDS NOVO NORDISK A/S (DK) 2001-09-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030135056-A1 Imidazole compounds HRH3, HRH4, HRH2 KDM4E 2142/4885ALDH1A1 1600/4885MEN1 1139/4885
US-20020058659-A1 Imidazole compounds HRH3, HRH4, HRH2 KDM4E 2142/4885ALDH1A1 1600/4885MEN1 1139/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.